Cara Therapeutics Inc. (NASDAQ: CARA) has announced its operational and financial results for the third quarter ending September 30, 2021, in which revenue was $20.3 million...
Cara Therapeutics Inc (NASDAQ: CARA) and Vifor Pharma have announced that the U.S Food and Drug Administration (FDA) has approved KORSUVA™ (difelikefalin) to treat moderate to...
Cara Therapeutics Inc. (NASDAQ: CARA) has announced its Q2 2021 financial results and its operational results for the period ending June 30, 2021. Cara didn’t recognize...